

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE AS MANY SHEETS AS NECESSARY)				ATTY. DOCKET NO.: DX0724XK1D SERIAL NO.: TBA APPLICANT: Gerard T. Hardiman EXAMINER NAME: TBA FILING DATE: 04/09/2008 ART UNIT: TBA	
Sheet 1 of 8					
U.S. PATENT DOCUMENTS					
*EXAMINER INITIAL	CITE NO. ¹	DOCUMENT NUMBER	PUB. DATE.	NAME OF PATENTEE OR APPLICANT	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	5,853,977	12/29/1998	Dalie et al.	
	AB	5,350,836	09/27/1994	Kopchick et al.	
Examiner signature:			Date considered:		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14.

This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE AS MANY SHEETS AS NECESSARY)				ATTY. DOCKET NO.: DX0724XX1D		SERIAL NO.: TBA	
				APPLICANT:			
				Gerard T. Hardiman			
				EXAMINER NAME:			
				TBA			
				FILING DATE:		ART UNIT:	
				04/09/2008		TBA	
Sheet 2 of 8							
FOREIGN PATENT DOCUMENTS							
*EXAMINER INITIAL	CITE NO. ¹	DOCUMENT NUMBER	PUB. DATE.	NAME OF PATENTEE OR APPLICANT	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		T ⁶
	AC	WO 98/02557	01/22/1998	Schering Corp.			
	AD	WO 98/50547	11/12/1998	Schering Corp.			
	AE	WO 99/20756	04/29/1999	Genentech, Inc.			
	AF	WO 00/24776	05/04/2000	Japan Science and Technology Corp.			
	AG	WO 01/62922	08/30/2001	Incyte Genomics, Inc.			
	AH	WO 01/55386	08/02/2001	Glaxo-Smithkline			
Examiner signature:				Date considered:			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14.

This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449/PTO		ATTY. DOCKET NO.: DX0724XK1D	SERIAL NO.: TBA
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE AS MANY SHEETS AS NECESSARY)		APPLICANT: Gerard T. Hardiman	
		EXAMINER NAME: TBA	
		FILING DATE: 04/09/2008	ART UNIT: TBA
Sheet 3 of 8			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
Examiner initials*	Cite no. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	

AI	M.D. ADAMS, <i>et al.</i> , <u>GenBank</u> , Accession No. AA381849, April 21, 1997. Definition: "EST94973 Activated T-cells I Homo sapiens cDNA 5' end similar to similar to H. sapiens hypothetical protein (GP:D13637_1), mRNA sequence."
AJ	MARK D. ADAMS, <i>et al.</i> , <u>Nature</u> , 377:3-17, September 28, 1995. "Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence"
AK	JAMES W. BAUMGARTNER, <i>et al.</i> , <u>J. Biological Chemistry</u> , 269(46):29094-29101, 1994. "The Role of the WSXWS Equivalent Motif in Growth Hormone Receptor Function"
AL	MARCIA P. BELVIN, <i>et al.</i> , <u>Annu. Rev. Cell Dev. Biol.</u> , 12:393-416, 1996. "A CONSERVED SIGNALING PATHWAY: The <i>Drosophila</i> Toll-Dorsal Pathway"
AM	IRWIN M. CHAIKEN and WILLIAM V. WILLIAMS, <u>TIBTECH</u> , 14:369-375, 1996. "Identifying structure-function relationships in four-helix bundle cytokines: towards de novo mimetics design"
AN	CHARLES A. DINARELLO, <u>Blood</u> , 87(6):2095-2147, March 15, 1996. "Biologic Basis for Interleukin-1 in Disease"
AO	CHARLES A. DINARELLO, <u>Blood</u> , 77(8):1627-1652, April 15, 1991. "Interleukin-1 and Interleukin-1 Antagonism"
AP	CHARLES A. DINARELLO, <u>The FASEB Journal</u> , 8:1314-1325, December 1994. "The interleukin-1 family: 10 years of discovery"
AQ	DAVID G. GEORGE, <i>et al.</i> , <u>Macromolecular Sequencing and Synthesis Selected Methods and Applications</u> , Ch 12, pp 127-149, 1988. "Current Methods in Sequence Comparison and Analysis"
AR	I.R. GIBBONS, <i>et al.</i> , <u>Proc. Natl. Acad. Sci. USA</u> , 88:8563-8567, October 1991. "A PCR procedure to determine the sequence of large polypeptides by rapid walking through a cDNA library"
AS	THOMAS J. GONDA and RICHARD J. D'ANDREA, <u>Blood</u> , 89(2):355-369. "Activating Mutations in Cytokine Receptors: Implications for Receptor Function and Role in Disease"

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE AS MANY SHEETS AS NECESSARY)

ATTY. DOCKET NO.:
DX0724XK1DSERIAL NO.:
TBAAPPLICANT:
Gerard T. HardimanEXAMINER NAME:
TBAFILING DATE:
04/09/2008ART UNIT:
TBA

Sheet 4 of 8

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner initials*	Cite no. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
--------------------	-----------------------	---	--------

AT	GARY HARDIMAN, <i>et al.</i> , <u>Oncogene</u> , 13:2467-2475, 1996. "Molecular characterization and modular analysis of human <i>MyD88</i> "
AU	M. HIBI, <i>et al.</i> , <u>GenBank</u> , Accession No.M57230, January 5, 1995. Definition: "Human membrane glycoprotein gp130 mRNA, complete cds."
AV	L. HILLIER, <i>et al.</i> , <u>GenBank</u> , Accession No.AA042999, May 10, 1997. Definition: "zk56c03.r1 Soares_pregnant_uterus_NbHPU Homo sapiens cDNA clone IMAGE:486820 5', mRNA sequence."
AW	L. HILLIER, <i>et al.</i> , <u>GenBank</u> , Accession No.AA707766, December 24, 1997. Definition: "zh24d04.s1 Soares_pineal_gland_N3HPG Homo sapiens cDNA clone IMAGE:412999 3', mRNA sequence."
AX	L. HILLIER, <i>et al.</i> , <u>GenBank</u> , Accession No.AA005049, 09-MAY-1997. Definition: "zh96c04.r1 Soares_fetal_liver_spleen_1NFLS_S1 Homo sapiens cDNA clone IMAGE:429126 5', mRNA sequence"
AY	L. HILLIER, <i>et al.</i> , <u>GenBank</u> , Accession No.H48602, 15-SEP-1995. Definition: "yq80b01.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:202057 5' similar to SP:TOLL_DROME P08953 TOLL PROTEIN ;, mRNA sequence"
AZ	L. HILLIER, <i>et al.</i> , <u>GenBank</u> , Accession No.N41021, 22-JAN-1996. Definition: "yy53b03.s1 Soares_multiple_sclerosis_2NbHMSP Homo sapiens cDNA clone IMAGE:277229 3', mRNA sequence"
BA	L. HILLIER, <i>et al.</i> , <u>GenBank</u> , Accession No.R76150, 06-JUN-1995. Definition: "yi71d02.r1 Soares placenta Nb2HP Homo sapiens cDNA clone IMAGE:144675 5', mRNA sequence"
BB	L. HILLIER, <i>et al.</i> , <u>GenBank</u> , Accession No.T60365, 13-FEB-1995. Definition: "yb90h06.r1 Stratagene liver (#937224) Homo sapiens cDNA clone IMAGE:78491 5', mRNA sequence"
BC	DAN HULTMARK, <u>Nature</u> , 367:116-117, January 13, 1994. "Ancient relationships"
BD	A.D. LARSEN, <u>GenBank</u> , Accession No.X55721, February 6, 1991. Definition: "Human mRNA coding for granulocyte colony stimulating factor receptor 25-1."
BE	BRUNO LEMAITRE, <i>et al.</i> , <u>Cell</u> , 86:973-983, September 20, 1996. "The Dorsoventral Regulatory Gene Cassette <i>spätzle/Toll/cactus</i> Controls the Potent Antifungal Response in <i>Drosophila</i> Adults"

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE AS MANY SHEETS AS NECESSARY)

ATTY. DOCKET NO.:
DX0724XK1DSERIAL NO.:
TBAAPPLICANT:
Gerard T. HardimanEXAMINER NAME:
TBAFILING DATE:
04/09/2008ART UNIT:
TBA

Sheet 5 of 8

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner initials*	Cite no. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
--------------------	-----------------------	---	----------------

BF	PATRICK LEMAIRE and LAURENT KODJABACHIAN, <u>Trends in Genetics</u> , 12(12):525-531, December 1996. "The vertebrate organizer: structure and molecules"
BG	MARK A. LEMMON and JOSEPH SCHLESSINGER, <u>TIBS</u> , 19:459-463, November 1994. "Regulation of signal transduction and signal diversity by receptor oligomerization"
BH	M. MARRA, <i>et al.</i> , <u>GenBank</u> , Accession No.AA266744, 21-MAR-1997. Definition: "mz93d07.r1 Soares mouse lymph node NbMLN Mus musculus cDNA clone IMAGE:720973 5', mRNA sequence."
BI	M. MARRA, <i>et al.</i> , <u>GenBank</u> , Accession No.AA288480, 04-APR-1997. Definition: "vb16a09.r1 Soares mouse 3NbMS Mus musculus cDNA clone IMAGE:749080 5', mRNA sequence."
BJ	R. MEDZHITOV, <i>et al.</i> , <u>GenBank</u> , Accession No.U93091, 30-NOV-1998. Definition: "Human Toll protein homolog mRNA, complete cds and LINE-1 reverse transcriptase homolog, pseudogene"
BK	RUSIAN MEDZHITOV, <i>et al.</i> , <u>Nature</u> , 388:394-397, July 24, 1997. "A human homologue of the Drosophila Toll protein signals activation of adaptive immunity"
BL	DONALD MORISATO & KATHYRN V. ANDERSON, <u>Annu. Rev. Genetics</u> , 29:371-399, 1995. "SIGNALING PATHWAYS THAT ESTABLISH THE DORSAL-VENTRAL PATTERN OF THE DROSOPHILA EMBRYO"
BM	D. MUZNY, <i>et al.</i> , <u>GenBank</u> , Accession No.AC003046, AC002362, AC002363, 06-JAN-1998. Definition: "Homo sapiens Xp22 PACs RPC11-263P4 and RPC11-164K3 complete sequence."
BN	NCI-CGAP, <u>GenBank</u> , Accession No.AA740990, 07-FEB-1998. Definition: "nz05g01.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:1286928 3' similar to TR:Q15399 Q15399 ORF, COMPLETE CDS. ;, mRNA sequence."
BO	NCI-CGAP, <u>GenBank</u> , Accession No.AA741118, 07-FEB-1998. Definition: "nz04f11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:1286829 3', mRNA sequence."
BP	NCI-CGAP, <u>GenBank</u> , Accession No.AA252405, 13-AUG-1997. Definition: "zs12e09.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:685000 5', mRNA sequence."
BQ	NOBUO NOMURA, <i>et al.</i> , <u>DNA Research</u> 1:27-35, 1994. "Prediction of the Coding Sequences of Unidentified Human Genes. I. The Codong Sequences of 40 New Genes (KIA A0001-KIA A0040) Deduced by Analysis of Randomly Sampled cDNA Clones from Human Immature Myeloid Cell Line KG-1"

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449/PTO		ATTY. DOCKET NO.: DX0724XX1D	SERIAL NO.: TBA
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE AS MANY SHEETS AS NECESSARY)		APPLICANT: Gerard T. Hardiman	
		EXAMINER NAME: TBA	
		FILING DATE: 04/09/2008	ART UNIT: TBA
Sheet 6 of 8			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
Examiner initials*	Cite no. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
		T ²	

BR	N. NOMURA, <u>GenBank</u> , Accession No.D13637, 10-JUL-1997. Definition: "Human mRNA for KIAA0012 gene, complete cds."
BS	HARUKI OKAMURA, <i>et al.</i> , <u>Nature</u> , 378:88-91, November 2, 1995. "Cloning of a new cytokine that induces IFN- γ production by T cells"
BT	K. OKUBO, <u>GenBank</u> , Accession No. C01399, 23-JUL-1996. Definition: "HUMGS0008381 Human adult (K. Okubo) Homo sapiens cDNA, mRNA" sequence."
BU	JAY D. PARKER, <i>et al.</i> , <u>Nucleic Acids Research</u> , 19(11):3055-3060, June 11, 1991. "Targeted gene walking polymerase chain reaction"
BV	D.H. PRESKY, <i>et al.</i> , <u>GenBank</u> , Accession No.U64198, November 26, 1996. Definition: "Human IL-12 receptor beta2 mRNA, complete cds."
BW	FERNANDO L. ROCK, <i>et al.</i> , <u>Proc. Natl. Acad. Sci. USA</u> , 95:588-593, January 1998. "A family of human receptors structurally related to <i>Drosophila</i> Toll"
BX	MARCO ROSETTO, <i>et al.</i> , <u>Biochem. Biophys. Res. Com.</u> , 209(1):111-116, April 6, 1995. "SIGNALS FROM THE IL-1 RECEPTOR HOMOLOG, TOLL, CAN ACTIVATE AN IMMUNE RESPONSE IN <i>DROSOPHILA</i> HEMOCYTE CELL LINE"
BY	J. SAMBROOK, <i>et al.</i> , <u>Molecular Cloning</u> , 2 nd , Volume 3:Chapter 17, Cold Spring Harbor Laboratory Press, 1989. "Expression of Cloned Genes in <i>Escherichia coli</i> "
BZ	VENKATAKRISHNA SHYAMALA and GIOVANNA FERRO-LUZZI AMES, <u>GENE</u> , 84:1-8, 1989. "Genome walking by single-specific-primer polymerase chain reaction: SSP-PCR"
CA	P. VERHASSELT, <i>et al.</i> , <u>DNA Sequence - J. DNA Sequencing and Mapping</u> , 2:281-287, 1992. "DNA sequencing by a subcloning-walking strategy using a specific and semi-random primer in the polymerase chain reaction"
CB	YANSHU WANG, <i>et al.</i> , <u>J. Biological Chemistry</u> , 271(8):4468-4476, February 23, 1996. "A Large Family of Putative Transmembrane Receptors Homologous to the Product of the <i>Drosophila</i> Tissue Polarity Gene <i>frizzled</i> "
CC	STEVEN A. WASSERMAN, <u>Molecular Biology of the Cell</u> , 4:767-771, August 1993. "A Conserved Signal Transduction Pathway Regulating the Activity of the <i>rel</i> like Proteins Dorsal and NF- κ B"
CD	IAIN WILSON, <i>et al.</i> , <u>Current Biology</u> , 7(3):R175-R178, 1997. "Signaling pathways: A common theme in plants and animals?"
CE	TAKEUCHI <i>et al.</i> , "TLR6: A novel member of an expanding Toll-like receptor family", <i>Gene</i> , vol. 231, pp. 59-65 (1999).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449/PTO		ATTY. DOCKET NO.: DX0724XK1D	SERIAL NO.: TBA
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE AS MANY SHEETS AS NECESSARY)		APPLICANT: Gerard T. Hardiman	
		EXAMINER NAME: TBA	
		FILING DATE: 04/09/2008	ART UNIT: TBA
Sheet 7 of 8			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
Examiner initials*	Cite no. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CF	AKIRA <i>et al.</i> , "Toll-like receptors: critical proteins linking innate and acquired immunity", <i>Nature Immunology</i> , vol. 2, no. 8, pp. 675-680 (2001).	
	CG	PENNICA <i>et al.</i> , PNAS, Vol. 95, pages 14717-14722, December 1998	
	CH	HAYNES <i>et al.</i> , Electrophoresis, Vol. 19, pages 1862-1871, 1998	
	CI	KONOPKA <i>et al.</i> , PNAS, Vol. 83, pages 4049-4052, 1986	
	CJ	DataBase: A-Geneseq, Accession No: AAW86361, Ruben SM[WO9850547, 03/15/98]	
	CK	DataBase: PIR-80, Accession No. O00206, Medzhitove <i>et al.</i> , July 1997	
	CL	GOLENBOOK <i>et al.</i> , Nature Immunology, April 2001, Vol. 2, No. 4, pages 286-288.	
	CM	PEER BORK, "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle", <i>Genome Research</i> , 10:398-400 (2000)	
	CN	PEER BORK, "Go hunting in sequence databases but watch out for the traps, Trends in Genetics", Vol. 12:425-427 (October 1996)	
	CO	STEVEN E. BRENNER, "Errors in genome annotation, Trends in Genetics", Vol. 15:132-133 (April 1999)	
	CP	CHAUDHARY <i>et al.</i> , "Cloning and Characterization of Two Toll/Interleukin-1 Receptor-Like Genes TIL3 and TIL4: Evidence for a Multi-Gene Receptor Family in Humans", <i>Blood</i> , Vol. 91, No. 11:4020-4027 (June 1998)	
	CQ	CHIANG, <i>et al.</i> , "Expression of a Novel Toll-like gene spans the parasegment boundary and contribute to hedgehog function in the adult eye of Drosophila," <i>Mechanism of Development</i> , 47:225-239, (November 1994)	
	CR	DOERCKS <i>et al.</i> , "Protein annotation" detective work for function prediction, <i>Trends in Genetics</i> , Vol. 14:248-25- (June 1998)	
	CS	ELDON <i>et al.</i> , "The Drosophila 18 wheeler is required for morphogenesis and has striking similarities to Toll", <i>Development</i> 120:885-899 (April 1994)	
	CT	HAYNES, <i>et al.</i> , "Proteins analysis: Biological assay or data archive?", <i>Electrophoresis</i> , 19:1862-1871 (August 1998)	
	CU	KONOPKA <i>et al.</i> , "Variable expression of the translocated c-abl oncogene in Philadelphia-chromosome-positive B-lymphoid cells lines from chronic myelogenous leukemia patients, <i>Proc. Natl. Acad. Sci., USA</i> 83:4049-4052 (June 1986)	
	CV	MASSAGUE <i>et al.</i> , "The TGF-beta Family of Growth and Differentiation Factors", <i>Cell</i> , Vol. 49:437-438 (May 1987)	
Examiner signature:		Date considered:	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449/PTO		ATTY. DOCKET NO.: DX0724XK1D	SERIAL NO.: TBA
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE AS MANY SHEETS AS NECESSARY)		APPLICANT: Gerard T. Hardiman	
		EXAMINER NAME: TBA	
		FILING DATE: 04/09/2008	ART UNIT: TBA
Sheet 8 of 8			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
Examiner initials*	Cite no. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CW	MITCHAM et al., "T1/ST2 Signaling Establishes It as a Member of an Expanding Interleukin-1 Receptor Family", The Journal of Biological Chemistry, Vol. 271:5777-5783 (March 1996)	
	CX	PENNICA et al., "WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1 transformed cells and aberrantly expressed in human colon tumors", Vol. 95:14717-14722 (December 1998)	
	CY	PILBEAM et al., "Comparison of the Effects of Various Lengths of Synthetic Human Parathyroid Hormone-Related Peptide (hPTHrP) of Malignancy on Bone Resorption and Formation in Organ Culture", Bone 14:717-720 (September 1993)	
	CZ	ROCK, et al., "EMBL Assession No. U88878.1, Homo Sapiens Toll-like receptor 2 (TLR2) MRNA, Complete CDs., (October 3, 1997)	
	DA	SKOLNICK et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era", Trends in Biotechnology 18:34-39 (January 2000)	
	DB	SMITH et al., "The challenges of genome sequence annotation or "The devil is in the details", Nature Biotechnology, Vol. 15:1222-1223 (November 1997)	
	DC	TAGUCHI et al., "Chromosomal Localization of TIL, a Gene Encoding a Protein Related to the Drosophila Transmembrane Receptor Toll, to Human Chromosome 4p14, Genomics 32:486-488 (March 1996)	
	DE	VUKICEVIC et al., "Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7), Proc. Natl. Acad. Sci USA, Vol. 93:9021-9026 (August 1996)	
	DF	MUNZY et al., GenBank Accession No. AC006252, "Homo sapiens 3p21.1 contig 9 PAC RPC15-1157M23 (Roswell Park Cancer Institute Human PAC Library) complete sequence", December 29, 1998.	
Examiner signature:		Date considered:	

*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.